Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

Benzinga Newsdesk www.benzinga.com Neutral 61.5%

Neg 0% Neu 61.5% Pos 0%

Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.